Comparative Study of microRNA Changes in Patients With Reactive Lymphoid Hyperplasia and Malignant Lymphoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03167476

Enrollment

200

Registered

2017-05-30

Start date

2016-08-01

Completion date

2018-12-01

Last updated

2017-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperplasia Lymphoid Reactive, Lymphoma

Keywords

miRNA, biomarker

Brief summary

The objectives are to: 1. validate a panel of tissue-specific miRNAs that are differentially expressed in the tissue of patients with and without reactive hyperplasia and lymphoma. 2. investigate the physiological range of the miRNA panel in lymphoma and reactive hyperplasia subjects. 3. investigate the dysregulation of miRNA panel and their prognostic and predictive values in clinical outcomes to identifying patients with malignant lymphoma or reactive hyperplasia. The objectives are to: 1. validate a panel of tissue-specific miRNAs that are differentially expressed in the tissue of patients with and without reactive hyperplasia and lymphoma. 2. investigate the physiological range of the miRNA panel in lymphoma and reactive hyperplasia subjects. 3. investigate the dysregulation of miRNA panel and their prognostic and predictive values in clinical outcomes to identifying patients with malignant lymphoma or reactive hyperplasia. This trial involves tissue samples diagnosed as lymphoma and reactive hyperplasia. The investigators will develop panels of miRNAs that are specific biomarkers of lymphoma, and assist clinical outcomes with these miRNAs.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults 18 years and above * Has condition related to lymphoma or reactive lymphoid hyperplasia

Exclusion criteria

* Age below 18 years * Known pregnancy * lymph tissue cannot be accessed

Design outcomes

Primary

Measure	Time frame	Description
The concentration of miRNA expression quantitated in absolute copy numbers and their correlation in patients with reactive hyperplasia and lymphoma.	Three years	The concentration of tissue miRNAs in absolute quantification in comparison to reactive hyperplasia and lymphoma. To investigate the potential prognosis of lymphoma by the expression difference of the miRNA panel. Sensitivity, specificity and the potential scopes of selected miRNA in the miRNA panel to distinguish hyperplasia and lymphoma and against standard clinical outcome.

Countries

China

Contacts

Primary ContactJuanjuan Kang

kjj@immunet.cn+ 86-28-83202351

Outcome results